Home>>Lipids>> Fatty Amides>>N-Arachidonoyl-L-Serine

N-Arachidonoyl-L-Serine (Synonyms: ARA-S)

Catalog No.GC44320

Arachidonoyl amides of both amino acids and neurotransmitters such as dopamine have been previously reported in the literature.

Products are for research use only. Not for human use. We do not sell to patients.

N-Arachidonoyl-L-Serine Chemical Structure

Cas No.: 187224-29-9

Size Price Stock Qty
1mg
$26.00
In stock
5mg
$69.00
In stock
10mg
$103.00
In stock
25mg
$224.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Arachidonoyl amides of both amino acids and neurotransmitters such as dopamine have been previously reported in the literature. N-Arachidonoyl-L-serine (ARA-S) is one such recently isolated endocannabinoid with an unusual activity profile. ARA-S does not bind to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors or vanilloid receptor 1 (VR1). Like cannabidiol, ARA-S (5 mg/kg) antagonizes the hypotensive effects of a 10 mg/kg IV bolus of abnormal cannabidiol (Abn-CBD) in an anesthetized rat blood pressure model. However, similar to Abn-CBD, ARA-S relaxes isolated rat mesenteric arteries and abdominal aorta as well as increases phosphorylation of Akt and mitogen-activated protein kinase (MAPK) in HUVEC. The precise mechanisms of action by ARA-S and Abn-DBD in various vascular preparations appears to be different and requires further investigation.

Reviews

Review for N-Arachidonoyl-L-Serine

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-Arachidonoyl-L-Serine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.